Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Assets Average (2016 - 2025)

Historic Assets Average for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $912.1 million.

  • Intellia Therapeutics' Assets Average fell 2286.44% to $912.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $912.1 million, marking a year-over-year decrease of 2286.44%. This contributed to the annual value of $1.2 billion for FY2024, which is 1166.57% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Assets Average of $912.1 million as of Q3 2025, which was down 2286.44% from $942.5 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Assets Average ranged from a high of $1.5 billion in Q1 2023 and a low of $694.6 million during Q2 2021
  • In the last 5 years, Intellia Therapeutics' Assets Average had a median value of $1.2 billion in 2024 and averaged $1.1 billion.
  • Its Assets Average has fluctuated over the past 5 years, first surged by 13169.25% in 2021, then crashed by 2309.42% in 2025.
  • Intellia Therapeutics' Assets Average (Quarter) stood at $1.3 billion in 2021, then decreased by 0.95% to $1.3 billion in 2022, then dropped by 2.31% to $1.3 billion in 2023, then decreased by 7.07% to $1.2 billion in 2024, then decreased by 22.85% to $912.1 million in 2025.
  • Its Assets Average stands at $912.1 million for Q3 2025, versus $942.5 million for Q2 2025 and $1.1 billion for Q1 2025.